IART has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IART has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Integra Lifesciences Holdings's enterprise value is $1,934 Mil. Integra Lifesciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $222 Mil. Therefore, Integra Lifesciences Holdings's EV-to-EBITDA for today is 8.72.
The historical rank and industry rank for Integra Lifesciences Holdings's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Integra Lifesciences Holdings was 46.04. The lowest was 6.96. And the median was 21.74.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-10), Integra Lifesciences Holdings's stock price is $30.80. Integra Lifesciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.500. Therefore, Integra Lifesciences Holdings's PE Ratio for today is 61.60.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Integra Lifesciences Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | 28.02 | 23.69 | 17.70 | 15.32 | 18.66 |
Integra Lifesciences Holdings Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 16.05 | 14.16 | 15.35 | 18.66 | 10.36 |
For the Medical Devices subindustry, Integra Lifesciences Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's EV-to-EBITDA falls into.
Integra Lifesciences Holdings's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 1934.013 | / | 221.897 | |
= | 8.72 |
Integra Lifesciences Holdings's current Enterprise Value is $1,934 Mil.
Integra Lifesciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $222 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (NAS:IART) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Integra Lifesciences Holdings's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 30.80 | / | 0.500 | |
= | 61.60 |
Integra Lifesciences Holdings's share price for today is $30.80.
Integra Lifesciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Integra Lifesciences Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Chantal Veillon-berteloot | officer: EVP & CHRO | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Jeffrey Mosebrook | officer: SVP, Fin & PAO | 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Lea Daniels Knight | officer: EVP & CFO | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Eric Schwartz | officer: Corp VP, Gen Counsel & Sec | C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103 |
Witte Jan De | director, officer: President & CEO | C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123 |
Michael J. Mcbreen | officer: Executive VP & President, CSS | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Harvinder Singh | officer: Exec VP & PRES, International | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Lisa Evoli | officer: Chief Human Resources Officer | 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Raymond G. Murphy | director | 14604 CARROLTON ROAD, ROCKVILLE MD 20853 |
Renee Wonlai Lo | director | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Glenn Coleman | officer: CVP, CHIEF FINANCIAL OFFICER | C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Tru St Partnership, L.p. | 10 percent owner | 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085 |
Peter J Arduini | officer: President & COO | 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Shaundra Clay | director | 1100 CAMPUS ROAD, PRINCETON NJ 08540 |
Stuart Essig | director, officer: President and CEO | 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
From GuruFocus
By Marketwired • 11-02-2023
By PRNewswire • 10-24-2023
By PRNewswire • 11-14-2023
By Marketwired • 11-02-2023
By GuruFocus Research • 10-25-2023
By Marketwired • 10-23-2023
By PRNewswire • 11-14-2023
By Marketwired • 11-06-2023
By Marketwired • 10-20-2023
By PRNewswire • 11-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.